Rivulet Media (RIVU) 10-Q 9 May 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2016	Apr. 08, 2016
Document And Entity Information
Entity Registrant Name	Bio-Matrix Scientific Group, Inc.
Entity Central Index Key	1,079,282
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,459,257,450
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
CURRENT ASSETS
Cash	$ 118,850	$ 76,355
Prepaid Expenses	16,000	25,000
Note Receivable	12,051	12,051
Interest Receivable	1,978	$ 1,381
Due from Former Subsidiary Employee	15,000
Total Current Assets	163,879	$ 114,787
OTHER ASSETS
Deposits	4,200	4,200
Available for Sale Securities	57,273	159,720
Total Other Assets	61,473	163,920
TOTAL ASSETS	225,352	278,707
CURRENT LIABILITIES
Accounts Payable	162,907	167,977
Notes Payable	414,036	400,336
Bank Overdraft	0	0
Accrued Payroll	855,090	738,095
Accrued Payroll Taxes	44,491	44,485
Accrued Interest	350,407	324,750
Accrued Rent	15,000	10,000
Accrued Expenses	5,000	5,000
Convertible Note Payable Net of Unamortized Discount	228,044	231,507
Due to Affiliate	0	0
Due to Subsidiary Shareholder	0	0
Current portion, note payable to affiliated party	1,000	1,000
Total Current Liabilities	2,075,975	1,923,150
Long Term Liabilities
Convertible Note Payable Net of Unamortized Discount	58,295	0
Total Long Term Liabilities	58,295	0
Total Liabilities	2,134,270	1,923,150
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2,063,821 issued and outstanding as of September 30 2015 and March 31, 2016	207	207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized 94,852 issued and outstanding as of September 30, 2015 and March 31, 2016	9	9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015 and March 31, 2016	4	4
Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of March 31, 2016 and September 30,2015 respectively	73	73
Common Stock ($.0001 par value) 5,000,000,000 shares authorized and 4,232,931,345 issued and outstanding as of September 30, 2015, 8,000,000,000 shares authorized and 5,459,248,374 shares issued and outstanding as of March 31, 2016	545,922	423,292
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015 and March 31, 2016	0	0
Additional Paid in capital	32,200,217	29,004,809
Contributed Capital	509,355	509,355
Retained Earnings (Deficit)	(35,079,059)	(31,628,963)
Accumulated Other Comprehensive Income (Loss)	(137,726)	(35,280)
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.	(1,960,998)	(1,726,494)
Noncontrolling Interest in subsidiary	52,080	82,050
Total Stockholders' Equity	(1,908,918)	(1,644,444)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 225,352	$ 278,707

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - $ / shares	Mar. 31, 2016	Sep. 30, 2015
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Common stock; par value	$ 0.0001	$ 0.0001
Common Stock; shares authorized	8,000,000,000	5,000,000,000
Common stock; shares issued	5,459,248,374	4,232,931,345
Common stock; shares outstanding	5,459,248,374	4,232,931,345
Series AA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	100,000	100,000
Preferred stock; shares issued	94,852	94,852
Preferred stock; shares outstanding	94,852	94,852
Series AAA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	1,000,000	1,000,000
Preferred stock; shares issued	40,000	40,000
Preferred stock; shares outstanding	40,000	40,000
Series B
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	2,000,000	2,000,000
Preferred stock; shares issued	725,409	725,409
Preferred stock; shares outstanding	725,409	725,409
Non Voting
Preferred stock; par value	$ 1	$ 1
Preferred stock; shares authorized	200,000	200,000
Preferred stock; shares issued	0	0
Preferred stock; shares outstanding	0	0

Consolidated Statement of Opera

Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	172,096	22,969	277,417	25,206
General and Administrative	466,958	336,286	987,635	494,730
Consulting and Professional Fees	114,869	303,666	207,587	386,195
Rent	15,000	15,000	30,000	26,871
Total Costs and Expenses	768,923	677,922	1,502,639	933,003
OPERATING LOSS	(768,923)	(677,922)	(1,502,639)	(933,003)
OTHER INCOME & (EXPENSES)
Interest Income	297	291	597	551
Interest Expense	(12,686)	(1,869)	(25,657)	(33,265)
Loss on Settlement of Debt through Equity Issuance below Fair Value	(77,361)	(249,030)	(246,594)	(836,530)
Loss on Settlement of Debt through Issuance of Common Shares of Regen biopharma, Inc. below fair value	(364,822)	(8,179,432)	(1,528,135)	(8,179,432)
Interest Expense attributable to amortization of discount	$ (74,281)	(4,032)	$ (147,671)	(4,032)
Preferred Shares of Regen Biopharma, Inc. issued pursuant to contractual obligations		(3,154)		(3,154)
Expense related to issuance of Convertible Debt to Star City		(247,500)		(247,500)
Total Other Income & (Expense)	$ (528,852)	(8,701,551)	$ (1,947,457)	(9,303,362)
NET INCOME (LOSS)	(1,297,775)	(9,379,473)	(3,450,096)	(10,236,365)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	927,081	7,117,519	2,493,912	7,212,122
NET INCOME (LOSS) available to common shareholders	$ (370,694)	$ (2,261,954)	$ (956,184)	$ (3,024,243)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0001)	$ (0.0007)	$ (0.0002)	$ (0.0008)
Weighted average number of shares outstanding	5,092,829,323	3,172,885,208	4,903,011,524	3,663,947,530

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net Income	$ (1,297,775)	$ (9,379,473)	$ (3,450,096)	$ (10,236,365)
Add: Unrealized Gains on Securities		$ 1,000
Less: Unrealized Losses on Securities	$ (63,727)		$ (102,447)	$ (1,000)
Total Other Comprehensive Income (Loss)	(63,727)	$ 1,000	(102,447)	(1,000)
Comprehensive Income	$ (1,361,502)	$ (9,378,473)	$ (3,552,543)	$ (10,237,365)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (3,450,096)	$ (10,236,365)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Subsidiary Stock issued for services rendered by consultants	40
Interest Expense attributable to amortization of discount	147,671	$ 4,032
Additional paid in Capital	$ 495,461	$ 433,345
Impairment of Available for sale Securities
Loss on Settlement of Debt through Equity Issuance	$ 1,774,729	$ 9,015,962
Changes in operating assets and liabilities:
(Increase) Decrease in Prepaid Expenses	9,000
Increase (Decrease) in Accounts Payable	(5,071)	$ 187
Increase (Decrease) in Accrued Expenses	$ 147,658	107,362
Increase (Decrease) in bank Overdraft		(6,137)
(Increase) Decrease in Interest Receivable	$ (597)	$ (551)
(Increase) Decrease in Due from Former Employee	$ (15,000)
Decrease (Increase) Note Receivable		$ (1,629)
Net Cash Provided by (Used in) Operating Activities	$ (896,206)	$ (683,794)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in due to subsidiary shareholder
Stock in subsidiary sold for cash	$ 825,001
Principal borrowings (repayments) on notes and Convertible Debentures	13,700	$ 90,453
Principal borrowings (repayments) on Convertible Debentures	$ 100,000	$ 1,182,686
(Increase) Decrease in Deferred Financing Costs
Net Cash Provided by (Used in) Financing Activities	$ 938,701	$ 1,273,139
Net Increase (Decrease) in Cash	42,495	589,345
Cash at Beginning of Period	76,355	502
Cash at End of Period	118,850	589,847
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	$ 150,237	37,000
Common Shares of Regen Biopharma, Inc. issued for debt		$ 882,686

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Bio-Matrix Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc. From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet. On July 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation, (“BMSG”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by John Lauring. As a result of this transaction, the former stockholder of BMSG held approximately 80% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by BMSG under the purchase method of accounting, and was treated as a recapitalization with BMSG as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to August 2, 2005 (date of inception), of the reverse acquisition completed on July 3, 2006, and represent the operations of BMSG. Through its controlled subsidiary, Regen BioPharma, Inc., the Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. As of March 31, 2016 The Company holds 15 % of the equity and 64.7% of the voting power of Regen BioPharma, Inc. (“Regen”) A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and controlled subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011. Significant inter-company transactions have been eliminated. C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates. D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments as of March 31, 2016 consisted of Securities Available for Sale consisting of 8,066,667 common shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $12,051 . The fair value of Securities Available for sale as of March 31, 2016 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share. I. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the quarters ended March 31, 2016 and March 31, 2015. J. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows. In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Options and Warrants

Options and Warrants	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Options and Warrants	NOTE 3. OPTIONS AND WARRANTS As of March 31, 2016 the Company has no options or warrants outstanding.

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 4. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $312,327 recognized upon the deconsolidation of Entest Biomedical, Inc., the Company generated net losses of $34,727,737 (excluding $663,649 of Equity in Net Losses of Entest Biomedical, Inc. recognized) during the period from August 2, 2005 (inception) through March 31, 2016. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. . During the quarter ended December 31, 2015 Regen raised $560,000 through the issuance of equity securities for cash. During the quarter ended March 31, 2016 Regen raised $265,000 through the issuance of equity securities for cash and $100,000 through the issuance of convertible debentures.

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 5. INCOME TAXES As of March 31, 2016 Deferred tax assets: Net operating tax carry forwards $ 11,820,960 Other -0- Gross deferred tax assets 11,820,960 Valuation allowance (11,820,960 ) Net deferred tax assets $ -0- As of March 31, 2016 the Company has a Deferred Tax Asset of $ 11,820,960completely attributable to net operating loss carry forwards of approximately $34,766,353 ( which expire 20 years from the date the loss was incurred) consisting of (a) $38,616, of Net Operating Loss Carry forwards acquired in the reverse acquisition of BMSG and (b) $34,727,737 attributable to Bio-Matrix Scientific Group, Inc. a Delaware corporation, BMSG and Regen. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, the reverse acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0. Income tax is calculated at the 34% Federal Corporate Rate.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS As of March 31, 2016 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $71,986. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum. As of March 31, 2016 Regen is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $50. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to Regen by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month, As of March 31, 2016 Entest Biomedical, Inc. is indebted to Regen in the amount of $12,051. $12,051 lent by Regen to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. As of March 31, 2016 Regen is indebted to Blackbriar Partners in the amount of $3,000. $3,000 lent to Regen by Blackbriar Partners is due and payable February 19, 2017 and bears simple interest at a rate of 10% per annum. David R. Koos, the Chairman and Chief Executive Officer of the Company, also serves as the Chairman and CEO of Blackbriar Partners. On June 23, 2015 Regen Biopharma, Inc. entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby Regen Biopharma, Inc. granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen Biopharma, Inc. (“ License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a wholly owned subsidiary of Entest Biomedical, Inc. Pursuant to the Agreement, Zander shall pay to Regen Biopharma, Inc. one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on the first anniversary of the effective date of the Agreement and each subsequent anniversary. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance. Pursuant to the Agreement, Zander shall pay to Regen Biopharma, Inc. royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay Regen Biopharma, Inc. ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen Biopharma, Inc. receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to Regen Biopharma, Inc. minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by Regen Biopharma, Inc.: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to Regen Biopharma, Inc. with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen Biopharma, Inc. with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On September 28, 2015 Zander caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander as a license initiation fee. Regen Biopharma, Inc. recognized revenue of $192,000 equivalent to the fair value of 8,000,000 of the common shares of Entest Biomedical, Inc as of the date of issuance. David R. Koos serves as sole officer and director of both Zander and Entest Biomedical, Inc. and also serves as Chairman and Chief Executive Officer of Regen Biopharma, Inc.

Notes Payable and Convertible N

Notes Payable and Convertible Notes Payable and Notes Receivable	6 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes Payable	NOTE 7. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE AND NOTES RECEIVABLE March 31, 2016 Bio Technology Partners Business Trust (Company) $ 14,000 Bio Technology Partners Business Trust (Regen) $ 36,000 David R. Koos ( Company)( Note 6) $ 71,986 David R. Koos ( Regen)( Note 6) $ 50 The Sherman family Trust $ 2,000 Bostonia Partners ( Company) $ 98,000 Bostonia Partners ( Regen) $ 189,000 Blackbriar Partners $ 3,000 Total $ 414,036 Amounts due to the Biotechnology Partners Business Trust. are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. All loans to the Company and Regen made by David R. Koos are due and payable at the demand of Koos and bear simple interest at a rate of 15% per annum. All amounts due to the Sherman Family Trust bear no interest and are due and payable, in whole or in part, at the option of the holder. $60,000 lent to Regen Biopharma, Inc. by Bostonia Partners is due and payable September 16, 2016 and bear simple interest at a rate of 10% per annum $59,000 lent to Regen Biopharma, Inc. by Bostonia Partners is due and payable September 22, 2016 and bear simple interest at a rate of 10% per annum. 20,000 lent to Regen by Bostonia Partners is due and payable February 19, 2017 and bear simple interest at a rate of 10% per annum. 30,000 lent to Regen by Bostonia Partners is due and payable February 24, 2017 and bear simple interest at a rate of 10% per annum. 20,000 lent to Regen by Bostonia Partners is due and payable March 8, 2017 and bear simple interest at a rate of 10% per annum. $40,000 lent to the Company by Bostonia Partners is due and payable September 2, 2016 and bear simple interest at a rate of 10% per annum. $35,000 lent to the Company by Bostonia Partners is due and payable December 14, 2016 and bear simple interest at a rate of 10% per annum. $13,000 lent to the Company by Bostonia Partners is due and payable January 28, 2017 and bear simple interest at a rate of 10% per annum. 10,000 lent to the Company by Bostonia Partners is due and payable March 23, 2017 and bear simple interest at a rate of 10% per annum. 3,000 lent to Regen by Blackbriar Partners is due and payable February 19, 2017 and bear simple interest at a rate of 10% per annum. $ 50,000 Scott Levine $ 10,000 Mike and Ofie Weiner $ 18,400 Mike and Ofie Weiner $ 2,301 Bio Technology Partners Business Trust $ 149,763 Star City Capital, LLC $ 230,464 Total $149,763 due and payable to Starcity Capital LLC (“Note”) bears no interest, is payable on April1, 2016 and permits conversion at the Holder’s option into common shares of the Company under the following terms and conditions: The Holder of the Note is entitled, at its option, at any time after 180 days after March 27, 2015 to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (iii) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (iv) $0.0001. Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. other than as provided in (i), (ii) and(ii) above, the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than 9.99% of the Company’s outstanding common stock. The issuance of the Note amounted in a beneficial conversion feature of $300,000 which is amortized under the Interest Method over the life of the Note. The amount by which the instrument’s as converted value exceeds the principal amount as of March 31, 2016 is $149,763. $50,000 due and payable to Scott Levine bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 14, 2009. No demand for payment has been made. $10,000 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on March 3 , 2010. No demand for payment has been made. $18,400 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on December 28, 2009. No demand for payment has been made. $2,301 due and payable to Bio Technology Partners Business Trust bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 26, 2009. No demand for payment has been made. As of March 31, 2016 the unamortized discount on the Company’s convertible notes outstanding is $ 2428. Regen Biopharma, Inc. On March 8, 2016 (“Issue date”) Regen issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of Regen into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Regen shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by Regen from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by Regen of Regen’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by Regen to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize Regen’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of March 31, 2016 the unamortized discount on the convertible notes outstanding is $ 41,705. As of March 31, 2016 $100,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2016 is $25,000. NOTES RECEIVABLE March 31, 2016 Entest Biomedical, Inc. (Note 6) $ 12,051 Notes Receivable $ 12,051 $12,051 lent by Regen Biopharma, Inc. to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

Stockholders Equity

Stockholders Equity	6 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders Equity	NOTE 8. STOCKHOLDERS' EQUITY The stockholders' equity section of the Company contains the following classes of capital stock as of March 31, 2016: Preferred stock, $0.0001 par value; 20,000,000 shares authorized: 2,063,821 Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 94,852 Series AA Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 40,000 Series AAA Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times one hundred thousand (100,0000). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 725,409 Series B Preferred Shares, Par Value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series B Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times two (2). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series B Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Non Voting Convertible Preferred Stock, $1.00 Par value, 200,000 shares authorized, 0 shares issued and outstanding Each Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert. “CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P. “PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock. “TRADING DAY” shall mean a day on which the Principal Market shall be open for business. On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Non Voting Convertible Preferred shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Common stock, $ 0.0001 par value; 8,000,000,000 shares authorized: 5,459,248,374 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. COMMITMENTS AND CONTINGENCIES On April 12, 2013 a complaint (Complaint) was filed in the U.S. District Court Southern District of the State of new York against the Company, the Company’s Chairman and Does 1-50 by Star city Capital, LLC (“Plaintiff”) alleging securities fraud, common law fraud, negligent misrepresentation, breach of fiduciary duties and breach of contract in connection with the issuance of. The Plaintiff is also request declaratory relief from the Court. The action arises from the issuance and subsequent cancellation of 103,030,303 of the company’s common shares in satisfaction of $17,000 of convertible indebtedness of the Company held by the Plaintiff. The Plaintiff alleges that a cancellation notice sent by them to the Company’s transfer agent was meant to instruct the Transfer Agent simply to cancel the physical certificate in order that an equivalent number of shares may be transferred via DWAC to the Plaintiff’s stockbroker for the benefit of the Plaintiff. DWAC is the acronym for Deposit/Withdrawal At Custodian. The DWAC transaction system run by The Depository Trust Company (a.k.a. DTC or CEDE & CO) permits brokers and custodial banks, the DTC participants, to request the movement of shares to or from the issuer’s transfer agent electronically. A DWAC results in the crediting or debiting of shares to or from DTC’s book-entry account on the records of the issuer maintained by the transfer agent. The Company believes that the cancellation notice sent by the Plaintiff clearly represents a cancellation of the conversion notice itself. The convertible indebtedness held by the Plaintiff was convertible at Holder’s demand into the common shares of the Company’s stock at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg (the “Closing Bid Price”); provided that if the closing bid price for the common stock on the date in which the conversion shares are deposited into Holder’s brokerage account and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase price for the conversion shares would be adjusted such that the Discount shall be taken from the closing bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price(“Reset”). The Company and the Plaintiff had agreed on a limitation on conversion equal to 9.99% of the Company’s outstanding common stock. On February 2, 2015 Plaintiff and the Company entered into a Settlement Agreement and Mutual General Release to fully and finally resolve the aforementioned legal action pursuant to the following terms and conditions: (a) Within seven business days of the Company’s transfer agent’s receipt of an appropriate opinion of counsel, the Company shall deliver to Starcity or its designee or assignee (which designation or assignment shall be provided in writing) via DWAC, 103,030,303 of the common shares of the Company , it being the agreement of the parties that such issuance shall constitute full and complete satisfaction of $17,000 due to Starcity by the Company. (b) The Company shall deliver to Starcity a non interest bearing Convertible Note in the face amount of $300,000 (“Note”) due and payable April 1, 2016. The Holder of this Note is entitled, at its option, at any time after 180 days after the date that consideration of $52,500 is paid to the Company to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (i) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (ii) $0.0001. Other than as provided in 5(p) of the Note ), the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than to hold more than 9.99% of the Company's outstanding common stock. Section 5(p) of the Note states that: Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. In the event that Starcity fails to fund the Note by making a payment of $52,500 to the Company on or before April 1, 2015, the Company’s obligations under this Note shall be terminated, cancelled and relinquished. On August 21, 2012 the Company entered into a settlement funding agreement with Princeton Research, Inc. and Jan Vandersande (collectively the “PRI Parties”) which obligates the Company to pay the PRI Parties $1,000 a month over thirty months. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to Regen Biopharma, Inc. by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of Regen and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.

Investment Securities

Investment Securities	6 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Investment Securities	NOTE 10. INVESTMENT SECURITIES As of the quarter ending September 30, 2012 the Company reclassified 66,667 ( retroactively adjusted for reverse stock split.) common shares of Entest Biomedical, Inc. as Securities Available for Sale from Securities Accounted for under the Equity Method. On September 28, 2015 Zander Theraputics, Inc. caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander Theraputics, Inc as a license initiation fee. As of September 30, 2015 the Company recognized an other than temporary impairment of $41,333,361 on 8,066,667 Common Shares of Entest Biomedical, Inc. The Company concluded that such impairment should be recognized based primarily due to: (a) History of recurring losses for Entest Biomedical, Inc. (b) Large percentage decline in fair value during the Company’s period of ownership The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities as of March 31, 2016. 8,066,667 Common Shares of Entest Biomedical, Inc. Basis Fair Value Total Unrealized Losses in Other Comprehensive Income Net Unrealized Gain or (Loss )realized during the quarter ended March 31, 2016 195,000 57,273 (137,726) (63,726)

Stock Transactions

Stock Transactions	6 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Stock Transactions	NOTE 11. STOCK TRANSACTIONS BIO- MATRIX SCIENTIFIC GROUP, INC.: On February 5, 2016 the Company issued 139,132,221 of its Common Shares in satisfaction of $13,913 of convertible indebtedness. On February 16, 2016 the Company issued 203,411,136 of its Common Shares in satisfaction of $20,341 of convertible indebtedness. On March 1, 2016 the Company issued 227,639,088 of its Common Shares in satisfaction of $22,763 of convertible indebtedness REGEN BIOPHARMA, INC. Common Stock On January 28, 2016 Regen issued 2,000,000 of its Common Shares for cash consideration of $100,000. On January 29, 2016 Regen issued 30,000 of its Common Shares for cash consideration of $750. On February 2, 2016 Regen issued 270,000 of its Common Shares for cash consideration of $6,750. On February22, 2016 Regen issued 666,666 of its Common Shares for cash consideration of $33,333. On February22, 2016 Regen issued 1,000,000 of its Common Shares for cash consideration of $12,500. Series A Preferred Stock On January 28, 2016 Regen issued 1,000,000 shares of its Series A Preferred stock for cash consideration of $50,000. On January 29, 2016 Regen issued 300,000 shares of its Series A Preferred stock for cash consideration of $7,500. On February 22, 2016 Regen issued 333,333 shares of its Series A Preferred stock for cash consideration of $16,666. On March 22, 2016 the Company issued 3,000,000 shares of its Series A Preferred stock for cash consideration of $37,500.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	6 Months Ended
	Mar. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Restatement of Previously Issued Financial Statements	NOTE 12. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS Subsequent to the original issuance of the Company’s annual consolidated financial statements, the Company determined that: An other than temporary impairment of $41,333,361 on 8,066,667 Common Shares of Entest Biomedical, Inc. owned by the Company should be recognized as of September 30, 2015 due to the following factors: (a) History of recurring losses for Entest Biomedical, Inc. (b) Large percentage decline in fair value during the Company’s period of ownership BIOMATRIX SCIENTIFIC GROUP, INC. CONSOLIDATED BALANCE SHEET As of September 30, 2015 Adjustments As of September 30, 2015 As originally Reported Restated ASSETS CURRENT ASSETS Cash 76,355 76,355 Prepaid Expenses 25,000 25,000 Note Receivable 12,051 12,051 Interest Receivable 1,381 1,381 Total Current Assets 114,787 114,787 OTHER ASSETS Deposits 4,200 4,200 Available for Sale Securities 159,720 159,720 Total Other Assets 163,920 163,920 TOTAL ASSETS 278,707 278,707 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable 167,977 167,977 Notes Payable 400,336 400,336 Bank Overdraft 0 0 Accrued Payroll 738,095 738,095 Accrued Payroll Taxes 44,485 44,485 Accrued Interest 324,750 324,750 Accrued Rent 10,000 10,000 Accrued Expenses 5,000 5,000 Convertible Note Payable Net of Unamortized Discount 231,507 231,507 Due to Affiliate 0 0 Due to Subsidiary Shareholder 0 0 Current portion, note payable to affiliated party 1,000 1,000 Total Current Liabilities 1,923,150 1,923,150 Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2063821 issues and outstanding as of September 30 2015 207 207 Series AA Preferred ($0.0001 par value) 100,000 shares authorized 94,852 issued and outstanding as of September 30, 2015 9 9 Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015 4 4 Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of and September 30, 2015 73 73 Common Stock ($.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 issued and outstanding as of September 30, 2015 423,292 423,292 Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015 0 0 Additional Paid in capital 29,004,809 29,004,809 Contributed Capital 509,355 509,355 Retained Earnings (Deficit) 9,704,398 (41,333,361 ) (31,628,963 ) Accumulated Other Comprehensive Income (Loss) (41,368,641 ) 41,333,361 (35,280 ) Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc. (1,726,494 ) (1,726,494 ) Noncontrolling Interest in subsidiary 82,050 82,050 Total Stockholders' Equity (1,644,444 ) (1,644,444 ) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) 278,707 278,707

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	NOTE 13: SUBSEQUENT EVENTS On April 7, 2016 Regen issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to David Koos, Regen’s Chief Executive Officer, as consideration for efforts expended by Koos with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate.. On April 7, 2016 Regen issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Harry Lander , Regen’s President and Chief Scientific Officer, as consideration for efforts expended by Lander with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate. On April 7, 2016 Regen issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Tod Caven , Regen’s Chief Financial Officer, as consideration for efforts expended by Caven with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate. On April 7, 2016 Regen issued 1,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) in settlement of $10,000 of principal indebtedness.

Organization and Summary of S20

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and controlled subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011. Significant inter-company transactions have been eliminated.
USE OF ESTIMATES	C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates.
CASH EQUIVALENTS	D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments as of March 31, 2016 consisted of Securities Available for Sale consisting of 8,066,667 common shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $12,051 . The fair value of Securities Available for sale as of March 31, 2016 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input.
INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share.
ADVERTISING	I. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the quarters ended March 31, 2016 and March 31, 2015.
REVENUE RECOGNITION	J. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Deferred tax assets	As of March 31, 2016 Deferred tax assets: Net operating tax carry forwards $ 11,820,960 Other -0- Gross deferred tax assets 11,820,960 Valuation allowance (11,820,960 ) Net deferred tax assets $ -0-

Notes Payable and Convertible22

Notes Payable and Convertible Notes Payable and Notes Receivable (Tables)	6 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	March 31, 2016 Bio Technology Partners Business Trust (Company) $ 14,000 Bio Technology Partners Business Trust (Regen) $ 36,000 David R. Koos ( Company)( Note 6) $ 71,986 David R. Koos ( Regen)( Note 6) $ 50 The Sherman family Trust $ 2,000 Bostonia Partners ( Company) $ 98,000 Bostonia Partners ( Regen) $ 189,000 Blackbriar Partners $ 3,000 Total $ 414,036
Convertible Notes Payable	$ 50,000 Scott Levine $ 10,000 Mike and Ofie Weiner $ 18,400 Mike and Ofie Weiner $ 2,301 Bio Technology Partners Business Trust $ 149,763 Star City Capital, LLC $ 230,464 Total
Notes Receivable	March 31, 2016 Entest Biomedical, Inc. (Note 6) $ 12,051 Notes Receivable $ 12,051

Investment Securities (Tables)

Investment Securities (Tables)	6 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Comprehensive Income	Basis Fair Value Total Unrealized Losses in Other Comprehensive Income Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2016 195,000 57,273 (137,726) (63,726)

Restatement of Previously Iss24

Restatement of Previously Issued Financial Statements (Tables)	6 Months Ended
	Mar. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Restatement of Consolidated Balance Sheet	BIOMATRIX SCIENTIFIC GROUP, INC. CONSOLIDATED BALANCE SHEET As of September 30, 2015 Adjustments As of September 30, 2015 As originally Reported Restated ASSETS CURRENT ASSETS Cash 76,355 76,355 Prepaid Expenses 25,000 25,000 Note Receivable 12,051 12,051 Interest Receivable 1,381 1,381 Total Current Assets 114,787 114,787 OTHER ASSETS Deposits 4,200 4,200 Available for Sale Securities 159,720 159,720 Total Other Assets 163,920 163,920 TOTAL ASSETS 278,707 278,707 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable 167,977 167,977 Notes Payable 400,336 400,336 Bank Overdraft 0 0 Accrued Payroll 738,095 738,095 Accrued Payroll Taxes 44,485 44,485 Accrued Interest 324,750 324,750 Accrued Rent 10,000 10,000 Accrued Expenses 5,000 5,000 Convertible Note Payable Net of Unamortized Discount 231,507 231,507 Due to Affiliate 0 0 Due to Subsidiary Shareholder 0 0 Current portion, note payable to affiliated party 1,000 1,000 Total Current Liabilities 1,923,150 1,923,150 Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2063821 issues and outstanding as of September 30 2015 207 207 Series AA Preferred ($0.0001 par value) 100,000 shares authorized 94,852 issued and outstanding as of September 30, 2015 9 9 Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015 4 4 Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of and September 30, 2015 73 73 Common Stock ($.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 issued and outstanding as of September 30, 2015 423,292 423,292 Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015 0 0 Additional Paid in capital 29,004,809 29,004,809 Contributed Capital 509,355 509,355 Retained Earnings (Deficit) 9,704,398 (41,333,361 ) (31,628,963 ) Accumulated Other Comprehensive Income (Loss) (41,368,641 ) 41,333,361 (35,280 ) Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc. (1,726,494 ) (1,726,494 ) Noncontrolling Interest in subsidiary 82,050 82,050 Total Stockholders' Equity (1,644,444 ) (1,644,444 ) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) 278,707 278,707

Organization and Summary of S25

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jul. 03, 2006
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Acquired share capital of Bio-Maxtrix Scientific Gruop, Inc.			100.00%
Consideration of shares of common stock of the Company			10,000,000
Cancelation of shares of the Company owned and held by John Lauring			10,000,000
Percent of voting capital stock of the Company held by former stockholder of BMSG			80.00%
Owned subsidiary, Regen BioPharma, Inc.	15.00%
Voting power of subsidiary, Regen Bio Pharma, Inc.	64.70%
Shares of Entest BioMedical, Inc. for Securities Available for Sale	8,066,667
Note receivable from Entest BioMedical	$ 12,051
Valuation allowance	100.00%
Advertising expenses	$ 0	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		119 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Non-cash gain upon deconsolidation ofEntest Biomedical, Inc.			$ 313,327
Net Losses			34,727,737
Equity in Net Losses of Entest Biomedical, Inc.			$ 663,649
Proceeds from issuance of equity securities	$ 265,000	$ 560,000
Proceeds from issuance of convertible debentures	$ 100,000

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details)	Mar. 31, 2016USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 11,820,960
Other	0
Gross deferred tax assets	11,820,960
Valuation allowance	(11,820,960)
Net deferred tax assets	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Mar. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 11,820,960
Net operating loss carry forwards	34,766,353
Amount of NOL acuired in reverse aquisition fo BMSG	38,616
Amount of NOL attributable to Bio-Matrix Scientific Group, Inc.	$ 34,727,737
Federal Corporate income tax Rate	34.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	3 Months Ended	6 Months Ended
	Mar. 31, 2016USD ($)	Mar. 31, 2016USD ($)ft²	Sep. 28, 2015USD ($)shares
Rental space | ft²		2,300
Monthly Fee		$ 5,000
License fee		100,000
Royalties, receivable	$ 10,000	$ 10,000
Royalties receivable, percentage		4.00%
Stock received as license initiian fee, shares | shares			8,000,000
Stock received as license initiation fee, value			$ 100,000
Blackbriar Partners
Interest rate of note receivable	10.00%	10.00%
Notes payable to related party	$ 3,000	$ 3,000
Due date of note	Feb. 19, 2017
David Koos
Interest rate of note receivable	15.00%	15.00%
Notes payable to related party	$ 71,986	$ 71,986
Regen, David Koos
Interest rate of note receivable	15.00%	15.00%
Notes payable to related party	$ 50	$ 50
Regen
Interest rate of note receivable	10.00%	10.00%
Notes payable to related party	$ 12,051	$ 12,051

Notes Payable and Convertible30

Notes Payable and Convertible Notes Payable - Notes Payable (Details)	Mar. 31, 2016USD ($)
Notes Payable	$ 414,036
Blackbriar Partners
Notes Payable	3,000
Bio Technology Partners Business Trust (Company)
Notes Payable	14,000
Bio Technology Partners Business Trust (Regen)
Notes Payable	36,000
David R. Koos (Company)
Notes Payable	71,986
David R. Koos (Regen)
Notes Payable	50
The Sherman Family Trust
Notes Payable	2,000
Bostina Partners (Company)
Notes Payable	98,000
Bostina Partners (Regen)
Notes Payable	$ 189,000

Notes Payable and Convertible31

Notes Payable and Convertible Notes Payable - Convertible Notes Payable (Details)	Mar. 31, 2016USD ($)
Convertible Notes	$ 230,464
Scott Levine
Convertible Notes	50,000
Mike and Ofie Weiner (1)
Convertible Notes	10,000
Mike and Ofie Weiner (2)
Convertible Notes	18,400
Bio Technology Partners Business Trust
Convertible Notes	2,301
Star City Capital, LLC
Convertible Notes	$ 149,763

Notes Payable and Convertible32

Notes Payable and Convertible Notes Payable - Notes Receivable (Details)	Mar. 31, 2016USD ($)
Notes Receivable	$ 12,051
Entest Biomedical, Inc
Notes Receivable	$ 12,051

Notes Payable and Convertible33

Notes Payable and Convertible Notes Payable (Details Narrative)	3 Months Ended
	Mar. 31, 2016USD ($)$ / shares
Convertible notes	$ 230,464
Amount by which converted value exceeds principal	25,000
Unamortized discount on convertible notes	41,705
Notes Receivable	$ 12,051
Regen
Annual interest rate	10.00%
Convertible notes	$ 100,000
Convertible notes issued by subsidiary	$ 100,000
Convertible note issued by subsidiary, interest rate	8.00%
Convertible Note Terms	(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Regen shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by Regen from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by Regen of Regen’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by Regen to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize Regen’s proprietary NR2F6 intellectual property
Beneficial conversion feature	$ 42,600
Blackbriar Partners
Notes Payable	$ 3,000
Annual interest rate	10.00%
Maturity Date	Feb. 19, 2017
Bio Technology Partners Business Trust (Company)
Annual interest rate	10.00%
David R. Koos (Company)
Annual interest rate	15.00%
Bostina Partners (Regen)
Notes Payable	$ 60,000
Annual interest rate	10.00%
Maturity Date	Sep. 16, 2016
Bostina Partners (Regen) (2)
Notes Payable	$ 59,000
Annual interest rate	10.00%
Maturity Date	Sep. 22, 2016
Bostina Partners (Regen) (3)
Notes Payable	$ 20,000
Annual interest rate	10.00%
Maturity Date	Feb. 19, 2017
Bostina Partners (Regen) (4)
Notes Payable	$ 30,000
Annual interest rate	10.00%
Maturity Date	Feb. 24, 2017
Bostina Partners (Regen) (5)
Notes Payable	$ 20,000
Annual interest rate	10.00%
Maturity Date	Mar. 8, 2017
Bostina Partners (Company)
Notes Payable	$ 40,000
Annual interest rate	10.00%
Maturity Date	Sep. 2, 2016
Bostina Partners (Company) (2)
Notes Payable	$ 35,000
Annual interest rate	10.00%
Maturity Date	Dec. 14, 2016
Bostina Partners (Company) (3)
Notes Payable	$ 13,000
Annual interest rate	10.00%
Maturity Date	Jan. 28, 2017
Bostina Partners (Company) (4)
Notes Payable	$ 10,000
Annual interest rate	10.00%
Maturity Date	Mar. 23, 2017
Star City Capital, LLC
Convertible notes	$ 149,763
Maturity Date	Apr. 1, 2016
Convertible Note Terms	The Holder of the Note is entitled, at its option, at any time after 180 days after March 27, 2015 to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (iii) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (iv) $0.0001. Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. other than as provided in (i), (ii) and(ii) above, the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than 9.99% of the Company’s outstanding common stock.
Beneficial conversion feature	$ 300,000
Amount by which converted value exceeds principal	$ 357,165
Scott Levine
Annual interest rate	12.00%
Convertible notes	$ 50,000
Conversion price | $ / shares	$ 0.15
Maturity Date	Nov. 14, 2009
Mike and Ofie Weiner (1)
Annual interest rate	12.00%
Convertible notes	$ 10,000
Conversion price | $ / shares	$ .15
Maturity Date	Mar. 3, 2010
Mike and Ofie Weiner (2)
Annual interest rate	12.00%
Convertible notes	$ 18,400
Conversion price | $ / shares	$ .15
Maturity Date	Nov. 26, 2009
Bio Technology Partners Business Trust
Annual interest rate	12.00%
Convertible notes	$ 2,301
Conversion price | $ / shares	$ .15
Maturity Date	Nov. 26, 2009

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	6 Months Ended
	Mar. 31, 2016	Sep. 30, 2015
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Common stock; par value	$ 0.0001	$ 0.0001
Common Stock; shares authorized	8,000,000,000	5,000,000,000
Common stock; shares issued	5,459,248,374	4,232,931,345
Common stock; shares outstanding	5,459,248,374	4,232,931,345
Series AA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	100,000	100,000
Preferred stock; shares issued	94,852	94,852
Preferred stock; shares outstanding	94,852	94,852
Voting rights	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000).
Series AAA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	1,000,000	1,000,000
Preferred stock; shares issued	40,000	40,000
Preferred stock; shares outstanding	40,000	40,000
Voting rights	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times one hundred thousand (100,0000).
Series B
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	2,000,000	2,000,000
Preferred stock; shares issued	725,409	725,409
Preferred stock; shares outstanding	725,409	725,409
Voting rights	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series B Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times two (2).
Non-Voting
Preferred stock; par value	$ 1
Preferred stock; shares authorized	200,000
Preferred stock; shares issued	0
Preferred stock; shares outstanding	0
Conversion terms	Each Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	1 Months Ended	6 Months Ended
	Aug. 31, 2012USD ($)	Mar. 31, 2016USD ($)ft²	Feb. 02, 2015USD ($)	Apr. 12, 2013USD ($)shares
Commitments and Contingencies Disclosure [Abstract]
Cancellation of company common shares held by Plaintiff | shares				103,030,303
Satisfaction of convertible indebtedness held by Plaintiff				$ 17,000
Limitation on conversion of outstanding common stock				9.99%
Convertible Note to plaintiff, payable April 1, 2016			$ 300,000
Payment for consideration of note conversion			$ 52,500
Conversion discount rate			55.00%
Settlement with PRI Parties, payment per month	$ 1,000
Rental space | ft²		2,300
Monthly Fee		$ 5,000

Comprehensive Income_Loss (Deta

Comprehensive Income/Loss (Details)	3 Months Ended
	Mar. 31, 2016USD ($)
Accounting Policies [Abstract]
Basis	$ 195,000
Fair Value	57,273
Total Unrealized Losses in Other Comprehensive Income	(137,726)
Net Unrealized Gain or (Loss) realized	$ (63,726)

Investment Securities (Details

Investment Securities (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 28, 2015
Accounting Policies [Abstract]
Common shares reclassified	66,667
Stock issued as license fee, shares		8,000,000
Stock issued as license fee, value		$ 100,000
Common shares of Entest Biomedical, Inc	8,066,667
Other than temporary impairment recognized	$ 41,333,361

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 22, 2016	Mar. 01, 2016	Feb. 22, 2016	Feb. 16, 2016	Feb. 05, 2016	Feb. 02, 2016	Jan. 29, 2016	Jan. 28, 2016	Jan. 19, 2016	Sep. 30, 2015
Shares issued for cash, shares	5,459,248,374										4,232,931,345
Value of shares issued	$ 545,922										$ 423,292
Preferred stock issued	2,063,821										2,063,821
Preferred stock value	$ 207										$ 207
Common Stock
Common stock issued in satisfaction of convertible debt			227,639,088		203,411,136	139,132,221
Amount of convertible debt satisfied			$ 22,763		$ 20,341	$ 13,913
Common Stock | Regen
Shares issued for cash, shares		1,000,000		666,666			270,000	30,000	2,000,000
Value of shares issued		$ 12,500		$ 33,333			$ 6,750	$ 750	$ 100,000
Series A | Regen
Preferred stock issued		3,000,000		333,333					1,000,000	300,000
Preferred stock value		$ 37,500		$ 16,666					$ 50,000	$ 7,500

Restatement of Previously Iss39

Restatement of Previously Issued Financial Statements - Restatement of Consolidated Balance Sheet (Details) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
CURRENT ASSETS
Cash	$ 118,850	$ 76,355
Prepaid Expenses	16,000	25,000
Note Receivable	12,051	12,051
Interest Receivable	1,978	1,381
Total Current Assets	163,879	114,787
OTHER ASSETS
Deposits	4,200	4,200
Available for Sale Securities	57,273	159,720
Total Other Assets	61,473	163,920
TOTAL ASSETS	225,352	278,707
CURRENT LIABILITIES
Accounts Payable	162,907	167,977
Notes Payable	414,036	400,336
Bank Overdraft	0	0
Accrued Payroll	855,090	738,095
Accrued Payroll Taxes	44,491	44,485
Accrued Interest	350,407	324,750
Accrued Expenses	5,000	5,000
Convertible Note Payable Net of Unamortized Discount	228,044	231,507
Due to Subsidiary Shareholder	0	0
Current portion, note payable to affiliated party	1,000	1,000
Total Current Liabilities	2,075,975	1,923,150
Total Liabilities	2,134,270	1,923,150
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2,063,821 issued and outstanding as of September 30 2015	207	207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized 94,852 issued and outstanding as of September 30, 2015	9	9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015	4	4
Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of and September 30, 2015	73	73
Common Stock ($.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 issued and outstanding as of September 30, 2015	545,922	423,292
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015	0	0
Additional Paid in capital	32,200,217	29,004,809
Contributed Capital	509,355	509,355
Retained Earnings (Deficit)	(35,079,059)	(31,628,963)
Accumulated Other Comprehensive Income (Loss)	(137,726)	(35,280)
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.	(1,960,998)	(1,726,494)
Noncontrolling Interest in subsidiary	52,080	82,050
Total Stockholders' Equity	(1,908,918)	(1,644,444)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 225,352	278,707
As Originally Reported
CURRENT ASSETS
Cash		76,355
Prepaid Expenses		25,000
Note Receivable		12,051
Interest Receivable		1,381
Total Current Assets		114,787
OTHER ASSETS
Deposits		4,200
Available for Sale Securities		159,720
Total Other Assets		163,920
TOTAL ASSETS		278,707
CURRENT LIABILITIES
Accounts Payable		167,977
Notes Payable		400,336
Bank Overdraft		0
Accrued Payroll		738,095
Accrued Payroll Taxes		44,485
Accrued Interest		324,750
Accrued Rent		10,000
Accrued Expenses		5,000
Convertible Note Payable Net of Unamortized Discount		231,507
Due to Affiliate		0
Due to Subsidiary Shareholder		0
Current portion, note payable to affiliated party		1,000
Total Current Liabilities		1,923,150
Total Liabilities		1,923,150
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2,063,821 issued and outstanding as of September 30 2015		207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized 94,852 issued and outstanding as of September 30, 2015		9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015		4
Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of and September 30, 2015		73
Common Stock ($.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 issued and outstanding as of September 30, 2015		423,292
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015		0
Additional Paid in capital		29,004,809
Contributed Capital		509,355
Retained Earnings (Deficit)		9,704,398
Accumulated Other Comprehensive Income (Loss)		(41,368,641)
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.		(1,726,494)
Noncontrolling Interest in subsidiary		82,050
Total Stockholders' Equity		(1,644,444)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		278,707
Adjustments
STOCKHOLDERS EQUITY (DEFICIT)
Retained Earnings (Deficit)		(41,333,361)
Accumulated Other Comprehensive Income (Loss)		41,333,361
Restated
CURRENT ASSETS
Cash		76,355
Prepaid Expenses		25,000
Note Receivable		12,051
Interest Receivable		1,381
Total Current Assets		114,787
OTHER ASSETS
Deposits		4,200
Available for Sale Securities		159,720
Total Other Assets		163,920
TOTAL ASSETS		278,707
CURRENT LIABILITIES
Accounts Payable		167,977
Notes Payable		400,336
Bank Overdraft		0
Accrued Payroll		738,095
Accrued Payroll Taxes		44,485
Accrued Interest		324,750
Accrued Rent		10,000
Accrued Expenses		5,000
Convertible Note Payable Net of Unamortized Discount		231,507
Due to Affiliate		0
Due to Subsidiary Shareholder		0
Current portion, note payable to affiliated party		1,000
Total Current Liabilities		1,923,150
Total Liabilities		1,923,150
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2,063,821 issued and outstanding as of September 30 2015		207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized 94,852 issued and outstanding as of September 30, 2015		9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015		4
Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of and September 30, 2015		73
Common Stock ($.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 issued and outstanding as of September 30, 2015		423,292
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015		0
Additional Paid in capital		29,004,809
Contributed Capital		509,355
Retained Earnings (Deficit)		(31,628,963)
Accumulated Other Comprehensive Income (Loss)		(35,280)
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.		(1,726,494)
Noncontrolling Interest in subsidiary		82,050
Total Stockholders' Equity		(1,644,444)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		$ 278,707

Restatement of Previously Iss40

Restatement of Previously Issued Financial Statements - Restatement of Consolidated Balance Sheet (Details) (Parenthetical) - $ / shares	Mar. 31, 2016	Sep. 30, 2015
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,063,821	2,063,821
Preferred stock, shares outstanding	2,063,821	2,063,821
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	8,000,000,000	5,000,000,000
Common stock, shares issued	5,459,248,374	4,232,931,345
Common stock, shares outstanding	5,459,248,374	4,232,931,345
Non Voting
Preferred stock, par value (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series AA
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	94,852	94,852
Preferred stock, shares outstanding	94,852	94,852
Series AAA
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	40,000	40,000
Preferred stock, shares outstanding	40,000	40,000
Series B
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	725,409	725,409
Preferred stock, shares outstanding	725,409	725,409

Restatement of Previously Iss41

Restatement of Previously Issued Financial Statements (Details Narrative) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Temporary impairment		$ 41,333,361
Common stock, shares issued	5,459,248,374	4,232,931,345
Entest Biomedical, Inc.
Common stock, shares issued		8,066,667

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 07, 2016	Mar. 31, 2016	Mar. 22, 2016	Feb. 22, 2016	Jan. 28, 2016	Jan. 19, 2016	Sep. 30, 2015
Preferred stock issued		2,063,821					2,063,821
Preferred stock value		$ 207					$ 207
Series A | Regen
Preferred stock issued			3,000,000	333,333	1,000,000	300,000
Preferred stock value			$ 37,500	$ 16,666	$ 50,000	$ 7,500
Regen | Series A
Preferred stock issued	1,000,000
Preferred stock value	$ 10,000
Regen | Series A | David Koos
Preferred stock issued	10,000,000
Regen | Series A | Todd Caven
Preferred stock issued	10,000,000
Dr. Harry Lander | Series A | Regen
Preferred stock issued	10,000,000